Edison Investment Research - Telix Pharmaceuticals (TLX) Telix Pharmaceuticals - Regulatory progress in Japan and the US

Report

Edison Investment Research

Sean Conroy

Telix Pharmaceuticals - Regulatory progress in Japan and the US

Telix Pharmaceuticals is making progress on all fronts and recently announced that it has reached an agreement with the Japanese Pharmaceutical and Medical Device Agency (PMDA) to perform a 40-patient bridging study in Japan to support the approval of TLX250-CDx for the detection of renal cancer. Additionally, the company announced the details of its meeting with the FDA to discuss the NDA submission for illumet (TLX591-CDx), which appears to be near completion and may be submitted shortly.

16/09/2019 5 EN

Underlying

Telix Pharmaceuticals

Telix Pharmaceuticals Ltd. Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The Company's MTR products such as TLX-250 diagnosis and treatment of renal (kidney), TLX-591 treatment of metastatic castrate-resistant prostate cancer, and TLX-101 treatment of glioblastoma (brain cancer).

See profile

AU000000TLX2 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

GlobeNewsWire

Q1 2024 Revenue and Business Update

Q1 2024 Revenue and Business Update MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance The Company reports unaudited total revenue of US$114.9M1 (AU$175.0M), an increase of 18% on the prior quarter (US$97.1M2 or AU$148.1M). Revenue was primarily generated from sales of Telix’s prostate cancer imaging product Illuccix®. U.S. revenue grew by 18% to US$111.8M...

April 17, 2024 April 17, 2024 1 EN

GlobeNewsWire

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imagingCollaboration agreement announced for joint development and commercialisation with UCSF PharmaLogic announced as commercial manufacturing and pharmacy distribution partner MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma ima...

April 15, 2024 April 15, 2024 1 EN

GlobeNewsWire

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma probe used to detect radiation in patients and guide surgery. The patient was operated on at Hospital del Mar in Barcelona, Spain. SENSEI® is smaller than an AA battery and designed specifica...

March 26, 2024 March 26, 2024 1 EN

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

10h / 45m 10h / 45m 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

10h / 58m 10h / 58m 1 EN

Martyn King

Martyn King

Foxtons Group - FY24 underpinned by market share gains

Foxtons Group’s Q1 revenue grew by 9%, supported by growth in all three divisions as the strategic initiatives continue to gain significant momentum, driven by investment in staff, best-in-class bespoke IT and data platforms. This implies that Foxtons’ medium-term targets are now coming into focus. Market share is being gained in all divisions, which puts Foxtons in a good position as the sales market stabilises. We maintain our valuation of 132p/share and believe that if interest rates stabilise or ease further, there are upside risks to our forecasts.

11h / 16m 11h / 16m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Telix Pharmaceuticals - Regulatory progress in Japan and the US

Q1 2024 Revenue and Business Update

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Foxtons Group - FY24 underpinned by market share gains

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe